Clinical TrialMay 22, 2026, 08:31 AM
FibroBiologics CYPS317 psoriasis preclinical data positive
AI Summary
FibroBiologics announced positive preclinical data for its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting. The data showed that HDF spheroids reduced disease severity in mouse models, offered a favorable systemic safety profile, and sustained therapeutic efficacy with booster dosing. CYPS317 also demonstrated significant reductions in PASI scores and protected against hallmarks of psoriatic disease, indicating targeted immunomodulation.
Key Highlights
- FibroBiologics presented positive preclinical data for its CYPS317 program for psoriasis.
- HDF spheroids reduced disease severity in an imiquimod-induced psoriasis mouse model.
- Spheroids demonstrated a more favorable systemic safety profile than single-cell delivery.
- Booster dosing of HDF spheroids sustained therapeutic efficacy in a chronic-relapsing model.
- CYPS317 significantly reduced PASI scores and normalized monocyte-to-lymphocyte ratios.
- Histological analyses confirmed protection against epidermal thickening and immune cell infiltration.
- Data indicated targeted immunomodulation rather than broad immune suppression.
Price Impact
More from FBLG